Exelixis, Inc., is a biotechnology company engaged in the development of small molecule therapies for cancer. The Company was incorporated in Delaware as Exelixis Pharmaceuticals, Inc., in November 1994 and changed to Exelixis, Inc., in February 2000. The company's resources, R & D, and production focus on COMETRIQ (cabozantinib capsules, the company's wholly-owned multi-target receptor tyrosine kinase inhibitor). The company aims to develop COMETRIQ into a major licensed oncology product, and believes that the approval of COMETRIQ's treatment of deteriorating, metastatic MTC provides an opportunity to achieve this goal and establish a commercial position. 

EXEL

EXEL Profile